Participated · Equity · May 2026

DACC offers Clearing-as-a-Service aimed at financial institutions to support settlement and clearing needs. The company announced a $10 million strategic financing round from a group of investors including Conflux, Global InfoTech, Fosun International, Blockstone, Avior Capital, Fintech World, Satoshi Ventures, and BridgeTower. DACC intends to use the proceeds to build compliant financial settlement and clearing infrastructure. The company framed the round as strategic; no valuation, lead investor, prior funding details, or operating metrics were disclosed in the article. The announcement emphasizes compliance and infrastructure development as near-term priorities.

Led · Series B · May 2022

Robot++ was founded in 2015 and pivoted to high-altitude robotics in 2017 under founder Xu Huayang. The company builds specialty robots for scenarios such as ship rust removal, chemical tank anti-corrosion, wind turbine inspection and building cleaning, and emphasizes commercial deployment over demos. Robot++ reports nearly tenfold revenue growth over five years, overseas revenue that quadrupled year-on-year last year, and service to over 200 industry benchmark clients. Its ship rust removal robots claim over 70% market share in shipyards and have operated on more than 10,000 cargo vessels, while the company has accumulated over 2 million hours of operational industrial field data and tens of thousands of centimeter-level 3D scene models. Robot++ holds over 480 intellectual property rights and has national-level qualifications cited in the article. The company plans to expand global sales, scale deliveries, advance AI and embodied-intelligence integration, and pursue broader industrial ecosystem development.

Participated · Series C · Mar 2021

Thousand Oaks Biopharmaceuticals (澳斯康) is a CDMO and cell‑culture media biotech focused on integrated CMC biomanufacturing services spanning R&D, process development, production, logistics, technical support and after‑sales. Its affiliate Jianshun Bio (健顺生物) develops and manufactures serum‑free, chemically defined mammalian cell culture media and is described as a leading domestic supplier, serving 100+ clinical projects including over 20 phase‑III trials. On the CDMO side the company has served more than 40 clients since launching that business and reports rapidly growing annual orders. Operational assets include a 10,000 m2 cGMP facility with 2,000L batch and 500L perfusion production capacity and formulation lines for vial filling/lyophilization and pre‑filled syringes/cartridges; the company says it has passed audits to NMPA, FDA and EMA standards. The company states the new funding will be used to expand CDMO and media production capacity and to build a global‑scale media production base and an internationally leading CDMO platform. Thousand Oaks emphasizes an international management and technical team and positions its proprietary serum‑free media as enabling domestic substitution of previously imported products. Thousand Oaks Biopharmaceuticals is a biopharma firm. The company completed a Series B financing, raising 450 million yuan (about $64 million). The round was led jointly by CICC Capital’s sub‑fund CICC Jiatai and CITIC Securities’ private equity arm Goldstone Investment Limited. The article does not disclose the company’s product pipeline or future plans. No operating metrics (revenue, users) or use of proceeds are provided in the report. The financing strengthens the company’s capital base at the Series B stage. TOBIO is an integrated global CMC organization supplying GMP cell culture media and biomanufacturing capabilities. It offers integrated CMC services including cell line development from DNA sequences, process and bioanalytical development, customized cell culture media development, clinical material supply, commercial manufacturing, bioanalytical services and regulatory filings. The company closed a $45 million Series A to advance its phase II CDMO business and to fund construction of large-scale cell culture media (LSCCM) cGMP manufacturing facilities in Haimen, Nantong, China. TOBIO says the new plant will be the world’s largest cell culture medium manufacturing facility and will increase current media production capacity. Management frames the expansion as enabling strategic partnerships to accelerate biologics development from bench to market and to help partners provide affordable and accessible biologics. The company has global footprints in Shanghai, Haimen and Lanzhou in China, and Thousand Oaks and Pleasanton, California.

Participated · Series C · May 2020

Arterys is a San Francisco, CA-based global medical imaging platform that delivers clinical AI products over the internet. Led by co-founder and acting CEO John Axerio-Cilies, the company provides a web-based, AI-powered, FDA-cleared cloud-native viewer and platform. It operates a marketplace and ecosystem of partners to develop and deliver clinical applications built on its platform. The company raised $28m in a Series C to broaden that ecosystem and accelerate partner efforts. Arterys plans to extend its proprietary technology to application partners to make it easier for clinicians to integrate AI into their workflows from a single interface. The company emphasizes accelerating partners’ efforts to bring new clinical-grade AI applications to providers through its platform. Arterys is a San Francisco-based provider of a web-based AI platform for medical image analytics that enables physicians to process patient imaging cases with embedded AI algorithms. The cloud platform supports MRI and CT and offers image interpretation, case sharing, and automated reporting. Its proprietary technology protects patient information and complies with U.S. and EU data privacy regulations. Arterys' Cardiac MRI suite was the first product of its kind to obtain FDA clearance for use as a diagnostic support tool and is also cleared in Canada and the EU. The platform and cardiac MRI suite have been used to help diagnose more than 15,000 patients worldwide. The company plans to use the new funding to expand its web-based AI platform, launch oncology and neurology products, and accelerate commercialization of its cardiac offering. Arterys develops deep-learning diagnostic software for medical imaging that connects to standard MRI machines to enable non-invasive, precise quantitation of blood flow. The cloud-based platform uploads 10-minute chest MRI scans to a HIPAA-compliant server for computation and presents results in a web browser for clinician interaction and rapid approval of quantitative analyses. The solution targets cardiovascular applications including structural heart disease, congenital heart disease, carotid/neurovascular and renal vascular disease. The company plans to expand commercial operations for its visualization and quantification algorithm using proceeds from its recent Series A. The platform has regulatory clearances—CE Mark and U.S. FDA market clearance (March 2014)—and is already used for research at leading hospitals in the U.S. and Europe. Arterys anticipates broader distribution through ViosWorks in up to 7,000 GE MRI machines in H2 2016; the company is led by founder and CEO Fabien Beckers.

Led · Series B · May 2019

Crazy Dog is an internet-based pet supplies brand founded in 2014 and based in Jiangsu. Its core product offering includes dog food and other pet care merchandise sold on platforms such as Tmall, JD, and Amazon. The company sold more than 5 million bags of dog food last year and reported annual sales revenue of RMB 600 million in 2018. Crazy Dog works with over 3,000 pet clinics and plans to expand its offline presence by opening 20 stores in 2019. The company says it will use new capital to improve branding, services, merchandise range, and distribution channels. Founder Cui Jia emphasized that the business aims to move beyond solely selling dog food.